Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Siddiqui, B. A., Chapin, B. F., Jindal, S., Duan, F., Basu, S., Yadav, S. S., Gu, A.-D., Espejo, A. B., Kinder, M., Pettaway, C. A., Ward, J. F., Tidwell, R. S. S., Troncoso, P., Corn, P. G., Logothetis, C. J., Knoblauch, R., Hutnick, N., Gottardis, M., Drake, C. G., … Subudhi, S. K. (2023). Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal for ImmunoTherapy of Cancer, 11(3), e006262. https://doi.org/10.1136/jitc-2022-006262
Authors:
Bilal A. Siddiqui
Brian F. Chapin
Sonali Jindal
Fei Duan
Sreyashi Basu
Shalini S. Yadav
Ai-Di Gu
Alexsandra Espejo
Michelle Kinder
Curtis A. Pettaway
John F. Ward
Rebecca S.S. Tidwell
Patricia Troncoso
Paul G. Corn
Christopher J. Logothetis
Roland Knoblauch
Natalie A. Hutnick
Marco M. Gottardis
Charles G. Drake
Padmanee Sharma
Sumit K. Subudhi
Affiliated Authors:
Charles G. Drake
Columbia Affiliation:
Subjects:
Antineoplastic Agents (MeSH)
Prostatic Neoplasms (MeSH)
Cancer Immunotherapy (OpenAlex Topic)
Immunobiology of Dendritic Cells (OpenAlex Topic)
Natural Killer Cells in Immunity (OpenAlex Topic)
Author Keywords:
immunomodulation
immunotherapy
prostatic neoplasms
tumor microenvironment
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2022-006262
PMID:
36948506
DOI:
10.1136/jitc-2022-006262
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record

Record Created: